What does a platelet count of 800 × 10⁹/L, a lymphocyte count of 3.4 × 10⁹/L, and an eosinophil count of 0.7 × 10⁹/L indicate?

Interpretation of Laboratory Values

These laboratory values indicate thrombocytosis (elevated platelet count at 800 × 10⁹/L), with normal lymphocyte and mildly elevated eosinophil counts, requiring immediate investigation for underlying myeloproliferative neoplasms, reactive causes, and potential thrombotic risk.

Understanding the Abnormalities

Platelet Count: 800 × 10⁹/L (Markedly Elevated)

This represents thrombocytosis, defined as platelet count >450 × 10⁹/L. Normal range is 150-450 × 10⁹/L 1. At this level, you must distinguish between:

Primary (Clonal) Causes:

• Essential thrombocythemia (ET) - a myeloproliferative neoplasm requiring JAK2, CALR, or MPL mutation testing
• Polycythemia vera - check hematocrit, which should be <45% to exclude this 2
• Other myeloproliferative disorders

Secondary (Reactive) Causes:

• Iron deficiency anemia (check ferritin, iron studies)
• Acute blood loss or trauma
• Infection or inflammation (check CRP, ESR)
• Malignancy
• Rheumatoid arthritis or other inflammatory conditions 1

Lymphocyte Count: 3.4 × 10⁹/L (Normal)

This falls within the normal range of 1.0-4.8 × 10⁹/L. The normal lymphocyte count makes primary lymphoproliferative disorders less likely but does not exclude reactive processes.

Eosinophil Count: 0.7 × 10⁹/L (Mildly Elevated)

This represents mild eosinophilia, as the threshold is >0.45 × 10⁹/L 3. While not dramatically elevated, this finding is significant because:

• Eosinophilia is associated with prothrombotic states and correlates with higher platelet counts and fibrinogen levels 4
• This combination (thrombocytosis + eosinophilia) may increase thrombotic risk beyond either abnormality alone

Clinical Significance and Thrombotic Risk

The platelet count of 800 × 10⁹/L places this patient at increased risk for both thrombotic and hemorrhagic complications. In myeloproliferative neoplasms, platelet counts >600 × 10⁹/L are associated with:

• Increased thrombotic events (arterial and venous)
• Paradoxical bleeding risk due to acquired von Willebrand syndrome at very high counts
• Need for cytoreductive therapy 2

The concurrent mild eosinophilia may further amplify thrombotic risk through increased fibrinogen and platelet activation 4.

Immediate Diagnostic Workup Required

Complete Blood Count Review:

• Verify platelet count with peripheral blood smear (exclude platelet clumping artifact)
• Assess for platelet morphology abnormalities
• Check hemoglobin/hematocrit to evaluate for polycythemia vera
• Review white blood cell differential completely

Essential Laboratory Tests:

• JAK2 V617F mutation (positive in ~60% of ET, 95% of PV)
• CALR and MPL mutations if JAK2 negative
• Iron studies (ferritin, serum iron, TIBC) - iron deficiency is a common reactive cause
• CRP and ESR - assess for inflammatory/infectious causes
• Peripheral blood smear review by hematopathologist
• Comprehensive metabolic panel

If Travel History or Tropical Exposure:

• Stool microscopy for ova, cysts, and parasites (helminth infections cause eosinophilia) 3
• Schistosomiasis and strongyloides serology
• HIV testing (can present with eosinophilia) 3

Additional Considerations:

• Medication review (NSAIDs, antibiotics can cause eosinophilia) 3
• Assess for atopy (asthma, eczema, allergies)
• Bone marrow biopsy if myeloproliferative neoplasm suspected

Management Approach

Immediate Actions:

• Aspirin 81-100 mg daily should be initiated if no contraindications exist, particularly if ET or PV is suspected, to reduce thrombotic risk 2
• Avoid procedures with high bleeding risk until diagnosis clarified
• Assess for symptoms: headache, visual changes, erythromelalgia, pruritus (suggest myeloproliferative disorder)

Risk Stratification for Thrombosis:

• Age >60 years and/or prior thrombosis = high risk
• Requires cytoreductive therapy (hydroxyurea first-line) if platelet count >600 × 10⁹/L with high-risk features 2

Referral:

• Hematology consultation is mandatory for platelet counts >600 × 10⁹/L or if myeloproliferative neoplasm suspected
• Consider infectious disease referral if travel history and eosinophilia suggest parasitic infection 3

Common Pitfalls to Avoid

• Do not dismiss as "reactive" without excluding clonal disorders - missing ET or PV can lead to catastrophic thrombotic events
• Do not delay aspirin therapy while awaiting mutation results if myeloproliferative neoplasm is suspected
• Pseudothrombocytosis from platelet clumping must be excluded with smear review
• The mild eosinophilia should not distract from the primary concern of marked thrombocytosis, but both require explanation
• Do not assume iron deficiency without testing - it's a common reversible cause but requires confirmation